Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-5

  Vassilev, L ^a   Ranki, T ^a   Joensuu, T ^b   Jager E ^c   Karbach, J ^c   Wahle, C ^c   Partanen, K ^b   Kairemo, K ^b   Alanko, T ^b   Turkki, R ^d   Linder, N ^d   Lundin, J ^d   Ristimaki A ^d,e   Kankainen, M ^d   Hemminki, A ^e   Backman, C ^a   Dienel, K ^a   von Euler, M ^a   Haavisto, E ^a   Hakonen, T ^a   Juhila, J ^a   Jaderberg M ^a   Priha, P ^a   Vuolanto, A ^a   Pesonen, S ^a   more..

^a Oncos Therapeutics Ltd   (Finland)

^b Docrates Oncology Clinic   (Finland)

^c KRANKENHAUS NORDWEST   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anti tumor CD8C T cell; Anti tumor immunity; In situ vaccine; Th1 polarization; Tumor infiltrating lymphocyte; Viral immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CCL1 CHEMOKINE; EOTAXIN 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE DERIVED CHEMOKINE; ONCOS 102; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL INFILTRATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; OVARY CANCER;

EID: 84944457278     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1017702     Document Type: Article

References (25)

1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
2. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108:415-20; PMID:18037158; http://dx.doi.org/ 10.1016/j.ygyno.2007.10.016
3. Sato E,Olson SH,Ahn J, Bundy B,NishikawaH,Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a highCD8+/regulatory Tcell ratio are associatedwith favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/ 10.1073/pnas.0509182102
4. Curiel TJ,CoukosG, Zou L, Alvarez X,Cheng P,Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, BurowM, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
5. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900-12; PMID:23975756; http://dx.doi.org/ 10.1158/0008-5472.CAN-13-1550
6. Ascierto PA. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunol Immunother 2014; 64:271-4
7. Lavoué V, Thédrez A, Levêque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V, Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 2013; 11:147; PMID:23763830; http://dx.doi. org/10.1186/1479-5876-11-147
8. Webb JR,Milne K, Nelson BH. Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Oncoimmunol 2014; 3:e27668; PMID:25101220; http://dx.doi.org/10.4161/onci.27668
9. Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjatic S, et al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PloS One 2014; 9:e104099; PMID:25101620
10. Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Guckel B. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition? J Cancer Res Clin Oncol 2003; 129:397-409; PMID:12836015; http://dx.doi.org/ 10.1007/s00432-003-0445-7
11. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, Baroni G, Taddei GL. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005; 16(4):590-6; PMID:15699022; http://dx.doi.org/ 10.1093/annonc/mdi112
12. Shiver JW, Fu T-M, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 2002; 415:331-5; PMID:11797011; http://dx.doi.org/10.1038/415331a
13. Draper S, Heeney J. Viruses as vaccine vectors for infectious diseases and cancer. Nature Rev Microbiol 2010; 8:62-73; PMID:19966816; http://dx.doi.org/10.1038/nrmicro2240
14. Bart P-A, Huang Y, Karuna S, Chappuis S, Gaillard J, Kochar N, Shen X, AllenMA, Ding S, Hural J, et al. HIVspecific humoral responses benefit from stronger prime in phase Ib clinical trial. J Clin Invest 2014; 124(11):4843-56; PMID:25271627; http://dx.doi.org/10.1172/JCI75894
15. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18:1874-84; PMID:20664527; http://dx.doi.org/ 10.1038/mt.2010.161
16. Dranoff G. GM-CSF based cancer vaccines. Immunol Rev 2002; 188:147-154; PMID:12445288; http://dx. doi.org/10.1034/j.1600-065X.2002.18813.x
17. van der Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-3393; PMID:22323450; http://dx.doi.org/10.1182/blood-2011-11-370130
18. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID:24413387; http://dx.doi.org/10.1016/j.coi. 2013.12.005
19. Ghiringelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-648; PMID:16960692; http://dx.doi.org/10.1007/ s00262-006-0225-8
20. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen T, Laasonen L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19:1737-46; PMID:21673660; http://dx.doi.org/10.1038/ mt.2011.113
21. Brune IB, Wilke W, Hensler T, Holzmann B, Siewert JR. Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999; 177:55-60; PMID:10037309; http://dx.doi.org/10.1016/ S0002-9610(98)00299-2
22. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, CamusM, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx. doi.org/10.1126/science.1129139
23. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Rranslat Med 2012; 10:1-4; PMID:22214470; http://dx.doi.org/10.1186/1479-5876-10-1
24. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003; 34:605-609; PMID:12827615; http://dx.doi.org/10.1016/S0046-8177(03)00177-1
25. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-571; PMID:25428505; http:// dx.doi.org/10.1038/nature13954